Business & Industry

Jiangsu Hengrui Pharma has secured a landmark regulatory clearance in China for its oral thrombopoietin (TPO) receptor agonist hetrombopag, making it the first oral TPO agonist anywhere in the world to receive approval for chemotherapy-induced thrombocytopenia (CIT). The approval...

Gilead Sciences has expanded its R&D infrastructure with a new 182,000-square-foot facility in Foster City dedicated to inflammation, oncology, and data science.

Novartis has signed a landmark agreement with South Korean biopharmaceutical firm Alteogen, potentially valued at up to $3.22 billion, for the development and commercialisation of subcutaneous drug formulations powered by Alteogen's proprietary ALT-B4 technology. A Multi-Option Agreement Targeting Subcutaneous Formulation The...

Novo Nordisk has announced a strategic partnership with Amazon Web Services (AWS), naming it its preferred cloud provider and strategic AI partner, with the shared goal of accelerating drug discovery and modernising the company's technology infrastructure to prepare for...

The Trump administration is preparing to announce a new round of voluntary drug-pricing agreements with midsize biotech companies as early as August 31, 2026, according to sources familiar with the matter. The companies involved are expected to offer discounts on...

Huawei intends to deepen its artificial intelligence partnerships with pharmaceutical companies, according to William Zhang, president of the company's healthcare business unit, who confirmed to Reuters that the firm's current AI drug projects run predominantly with domestic Chinese drugmakers....

US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25 billion, a move aimed at strengthening its clinical research and biopharmaceutical commercialisation services. The McKesson acquisition remains subject to customary closing conditions, including regulatory approvals. Once...